US20040067889A1 - Stabilization of brain natriuretic peptide (BNP) in blood samples, methods and compositions related thereto - Google Patents

Stabilization of brain natriuretic peptide (BNP) in blood samples, methods and compositions related thereto Download PDF

Info

Publication number
US20040067889A1
US20040067889A1 US10/465,691 US46569103A US2004067889A1 US 20040067889 A1 US20040067889 A1 US 20040067889A1 US 46569103 A US46569103 A US 46569103A US 2004067889 A1 US2004067889 A1 US 2004067889A1
Authority
US
United States
Prior art keywords
bnp
phe
arg
ppack
stabilizing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/465,691
Other languages
English (en)
Inventor
Alexander Belenky
Barry Bluestein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Priority to US10/465,691 priority Critical patent/US20040067889A1/en
Assigned to BAYER CORPORATION reassignment BAYER CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BELENKY, ALEXANDER, BLUESTEIN, BARRY
Publication of US20040067889A1 publication Critical patent/US20040067889A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood

Definitions

  • the present invention relates to methods and compositions for reducing the proteolytic degradation of brain natriuretic peptide (BNP), thereby stabilizing this peptide, in blood based samples, such as plasma and serum.
  • BNP brain natriuretic peptide
  • BNP Brain natriuretic peptide
  • BNP is a vasoreactive cardiac peptide hormone which is synthesized and secreted into the bloodstream primarily from the heart ventricles.
  • This peptide hormone promotes natriuresis and diuresis, acts as a vasodilator and antagonizes the vasoconstrictor effects of renin-angiotensin-aldosterone system.
  • BNP as a diagnostic marker for identifying patients with heart disease, e.g., left ventricular systolic dysfunction, is complicated by the peptide's poor stability in blood samples.
  • the problem of preventing or significantly reducing BNP degradation in blood samples is still a viable one in the area of clinical chemistry and better methods and solutions for stabilizing BNP are needed.
  • the present invention provides a solution to the existing difficulty of stabilizing BNP so as to reduce or prevent its proteolytic degradation in blood samples.
  • FIG. 1 shows the effect of inhibitors on reducing the degradation of native (endogenous) BNP in a patient sample stored at 4° C. over time.
  • PPACK was used at a concentration of 35 ⁇ g/ml
  • leupeptin was used at a concentration of 50 ⁇ g/ml.
  • significantly more BNP was present at about 25 hours of storage at 4° C. compared with the sample containing no inhibitors.
  • FIG. 2 shows the effect of inhibitors on reducing the degradation of exogenous synthetic BNP (10,000 pg/ml) spiked into a human plasma pool (Intergen, Milford, Mass.).
  • BNP in human plasma was stabilized for nearly 30 days in the presence of inhibitors compared with plasma spiked with BNP in the absence of inhibitors.
  • AEBSF i.e., [4-(2-aminoethyl)benzenesulfonylfluoride]
  • AEBSF i.e., [4-(2-aminoethyl)benzenesulfonylfluoride]
  • antipain 100 ⁇ g/ml
  • benzamidine 14 mM
  • PPACK 35 ⁇ g/ml
  • the present invention provides a method for stabilizing BNP in a body fluid sample, particularly, a blood based sample, such as plasma or serum, preferably a plasma sample.
  • a blood based sample such as plasma or serum
  • stabilizing BNP reduces its degradation by endogenous proteases in the sample.
  • the method of the invention comprises the addition of stabilizing components to blood samples that contain BNP, either exogenously added or endogenous BNP, or to vessels or containers that will receive blood samples containing BNP.
  • the stabilizing components comprise one or more protease inhibitor compounds that reduce, protect against, or prevent proteolytic degradation of BNP.
  • the inhibitor compounds include acetyl-leu-leu-arginal (leupeptin), N-(N ⁇ -carbonyl-Arg-Val-Arg-al)Phe (antipain) and H-D-Phe-Phe-Arg-chloromethylketone (PPACK), as well as D-Phe-Pro-Arg-chloromethylketone (PPRACK) and diisopropylfluorophosphate (DFP).
  • the compounds can be used alone or in combination.
  • the combinations can comprise two, three, or more of the stabilizing components in admixture.
  • the inhibitor 4-(2-aminoethyl)benzenesulfonylfluoride (AEBSF), or compounds structurally related to AEBSF can be used alone or in combination with the foregoing inhibitors.
  • preferable BNP inhibitor combinations include leupeptin and PPACK; antipain and PPACK; leupeptin and PPRACK; antipain and PPRACK; leupeptin, antipain and PPACK; and leupeptin, antipain, PPRACK and DFP.
  • Preferred inhibitors, especially for practical applications, are PPACK or PPRACK.
  • the BNP inhibitors as described herein offer improved stabilization of BNP relative to previously used compounds.
  • the invention provides a stabilized composition of BNP comprising stabilizing inhibitor components, alone or in combination.
  • the composition can comprise components selected from PPACK alone; antipain alone, or leupeptin alone; a combination of leupeptin and PPACK; a combination of antipain and PPACK; a combination of leupeptin and antipain; a combination of leupeptin, antipain and PPACK; and a combination of leupeptin, antipain, PPACK and DFP, or analogs, variants, or derivatives thereof, or inhibitors which are structurally and/or functionally related thereto.
  • the stabilizing combination of components includes leupeptin and PPACK (or PPRACK).
  • the stabilizing components as described herein can be added to, i.e., spiked into, a blood sample to stabilize the endogenous BNP in the sample, and/or to stabilize exogenous BNP that can also be spiked into a sample.
  • the methods and compositions as described herein offer significant improvement of BNP stability in blood samples, including plasma and serum samples (e.g., Example 5).
  • the present invention provides a procedure for stabilizing BNP-containing blood samples by directly adding the above-mentioned inhibitor components, and combinations thereof, to collected blood samples, preferably plasma samples, prior to, at the time of, or shortly after collection and before testing in a laboratory or clinical setting, or before storage.
  • These components serve as BNP inhibitor additives to fresh samples, as well as to thawed samples, particularly, freshly thawed samples, of blood, plasma, or serum.
  • Preferred is the use of PPACK in an aqueous composition to stabilize BNP in fresh or thawed plasma.
  • the present invention provides a blood collection container or vessel, such as a vacuum tube (e.g., VacutainerTM) used in the collection of whole blood, comprising one, or a combination of, e.g., a cocktail of, the inhibitor components selected from, for example, antipain, leupeptin, PPACK, PPRACK and DFP.
  • a blood collection container or vessel such as a vacuum tube (e.g., VacutainerTM) used in the collection of whole blood, comprising one, or a combination of, e.g., a cocktail of, the inhibitor components selected from, for example, antipain, leupeptin, PPACK, PPRACK and DFP.
  • Blood samples particularly, BNP-containing samples, are collected in such blood collection vessels or containers having therein one or more of the inhibitors as described.
  • the pre-added inhibitor components such as leupeptin and PPACK, are present to stabilize BNP in a collected blood or plasma sample immediately upon introduction of the sample into the container or vessel.
  • the present invention provides stable plasma controls for BNP determination.
  • controls can be made by spiking a fixed amount of exogenously added BNP, e.g., a recombinantly produced or synthetic form of BNP, such as BNP-32, (D. R.
  • a human blood-based matrix e.g., a plasma matrix
  • the matrix contains one or more of the added inhibitor components according to the present invention, e.g., leupeptin, antipain, PPACK, PPRACK, DFP, or combinations thereof.
  • This feature of the invention overcomes prior difficulties in the preparation of plasma matrix controls due to the rapid degradation of spiked BNP by endogenous proteases during the preparation and value assignment procedure for such controls.
  • the present invention involves the introduction of at least one of, or a cocktail of a combination of, the inhibitor components antipain, leupeptin, PPACK, PPRACK, and/or DFP into BNP-containing blood samples, including plasma and serum samples.
  • the invention provides stable compositions comprising BNP and the inhibitor components.
  • the inclusion of the combination of leupeptin and PPACK to blood-based matrices prior to the addition of exogenous, e.g., synthetic, BNP provides a stable control material preparation, for example, for commercial controls of BNP that are stable in a human or animal plasma matrix.
  • the present invention relates to methods and compositions comprising one or more protease inhibitor components that inhibit or reduce the degradation of the cardiac peptide hormone BNP in blood samples, particularly plasma and serum samples.
  • BNP degradation during sample collection, storage and testing can cause falsely decreased or negative test results, and erroneous sample classification, for clinically or medically tested patient samples.
  • the addition of one or more of the newly determined BNP stabilizing components as described herein to blood, particularly blood plasma significantly reduces or inhibits BNP degradation and allows more accurate and reliable sample interpretation.
  • the methods and compositions involving the BNP stabilizing materials according to the present invention provide more accurate BNP concentration measurements in routine assays for the diagnosis and management of patients being tested for, or suspected to have, cardiac failure and/or cardiac disease.
  • the components which have been found, alone or in combination, e.g., as a cocktail of more than one component, to have superior BNP stabilizing properties according to this invention include the protease inhibitors acetyl-leu-leu-arginal (leupeptin); N-(N ⁇ -carbonyl-Arg-Val-Arg-al)Phe (antipain), (Sigma Aldrich, St.
  • AEBSF 4-(2-aminoethyl)benzenesulfonylfluoride
  • one or more of the above inhibitors stabilizes BNP and reduces or prevents its degradation by proteases in a blood (plasma) sample.
  • a blood (plasma) sample Alone, and in combination with antipain, leupeptin, or both, PPACK has been particularly newly found to vastly improve the stability of BNP.
  • the inhibitors preferably, leupeptin and PPACK, or antipain and PPACK, in combination, stabilized BNP in the samples at room temperature and at 4° C., even after repeated freezing and thawing. (Example 1).
  • the stabilizing capacity of the aforementioned inhibitors was determined based on an evaluation of the structure of BNP, which comprises regions that could be specifically sensitive to proteolysis, for example, a region of the circular portion of mature BNP-32 comprising the residues-Phe-Gly-Arg-. Accordingly, inhibitors of the present invention, e.g., PPACK and PPRACK without limitation, having structural similarity to the Phe-Gly-Arg residues comprising BNP, are especially suited to stabilizing BNP. Without wishing to be bound by theory, having a structural similarity to BNP provides an inhibitor with preferably better BNP-stabilizing function.
  • BNP can be modified so as to protect its intrinsic arginine (Arg) residues and related fragments from degradation, for example, by replacement of the natural amino acid residues involved in degradation of BNP-32 by molecules that can increase the resistance of BNP to proteolysis.
  • Arg arginine
  • a more stable BNP can contain D-Arg instead of native L-Arg.
  • more effective BNP stabilizing compounds can also be designed using this rationale.
  • the present invention also encompasses PPACK analogs, variants, or derivatives, (e.g., chemical analogs, variants, or derivatives), as well as inhibitors which are structurally and/or functionally related to leupeptin, antipain and PPACK, for use alone, or in combination, to stabilize BNP.
  • PPACK analogs, variants, or derivatives e.g., chemical analogs, variants, or derivatives
  • inhibitors which are structurally and/or functionally related to leupeptin, antipain and PPACK, for use alone, or in combination, to stabilize BNP.
  • Combinations of the regular forms of leupeptin, antipain and PPACK, i.e., non-variants or derivatives, with such analogs, variants and the like are also contemplated.
  • a nonlimiting example of a compound related to PPACK that is suitable for use according to the present invention is PPRACK (D-Phe-Pro-Arg-chloromethylketone), (Calbiochem, San
  • the inhibitors diisopropylfluorophosphate (DFP), (Calbiochem, San Diego, Calif.) and PPRACK have been shown to stabilize BNP as efficiently as antipain, leupeptin and PPACK. (See, Example 5, Table 11). Accordingly, the invention encompasses DFP and/or PPRACK used alone or in combination with one or more of antipain, leupeptin and PPACK in the compositions and methods described herein.
  • This invention embraces numerous practical applications, including, (i) adding the described BNP degradation inhibitors in the process of collecting blood or plasma samples to prevent sample BNP degradation during pre-test manipulations; (ii) adding the inhibitors to blood or plasma samples post-collection to prevent degradation of BNP during preparation for testing and during testing; and (iii) adding the inhibitors to plasma or a serum base for the preparation of controls, medical decision pools and the like, using either endogenous or synthetic BNP.
  • a method in which one or more of the stabilizing components leupeptin, antipain, PPACK, PPRACK, and/or DFP are introduced into human or animal blood samples to stabilize the BNP therein.
  • the sample is a plasma sample. More preferably, the sample is a human plasma sample.
  • the stabilization of BNP in blood samples of animals (mammals) other than humans, e.g., dogs, cats, cattle, horses, sheep, pigs, and the like, is also envisioned, such as for veterinary applications.
  • the BNP-stabilizing components of the present invention include the protease inhibitors leupeptin, antipain, PPACK, PPRACK, and/or DFP, which are used alone, or in combination, to stabilize BNP, i.e., reduce or eliminate its degradation, in a blood or plasma sample.
  • each inhibitor component shows efficacy in stabilizing BNP in plasma samples over time
  • combinations of the inhibitor components such as, for example, a combination of leupeptin and PPACK, or a combination of antipain and PPACK, or a combination of antipain, leupeptin and PPACK, yield significant BNP stabilizing effects over time at room temperature and 4° C., and upon thawing of frozen samples.
  • the methods and compositions of the present invention allow blood samples containing BNP to be accurately analyzed, with reliable values for BNP obtained, under conditions routinely encountered in medical practice, such as in clinics, clinical laboratories, hospital wards and physicians' offices.
  • the present invention provides advantageous methods and compositions to allow for more efficient, facile blood collection and transport of blood samples to a clinic or laboratory for BNP analysis.
  • the protease inhibitors as described herein are present in the sample in a BNP stabilizing amount.
  • acetyl-leu-leu-arginal leupeptin
  • leupeptin is present in a sample in an amount of from about 0.5 ⁇ g/ml to about 55 ⁇ g/ml, preferably from about 5 ⁇ g/ml to about 50 ⁇ g/ml and more preferably from 45 ⁇ g/ml to about 55 ⁇ g/ml
  • H-D-Phe-Phe-Arg-chloromethylketone (PPACK) or D-Phe-Pro-Arg-chloromethylketone (PPRACK) is present in a sample in an amount of from about 0.35 ⁇ g/ml to about 38 ⁇ g/ml, preferably from about 3.5 ⁇ g/ml to about 35 ⁇ g/ml, and more preferably from about 32 ⁇ g/ml to about 38 ⁇
  • Another embodiment of the invention embraces a stabilized composition
  • a stabilized composition comprising the BNP stabilizing components described herein, alone or in combination, in a plasma matrix, preferably, a human plasma matrix.
  • the stabilized composition which is suitable for use as a control for clinical and medical use, comprises one or more of leupeptin, antipain and/or PPACK which reduce or prevent proteolytic degradation of BNP in the sample, i.e., the plasma matrix.
  • the stabilized composition can comprise DFP and/or PPRACK alone, in combination with each other, or in combination with other inhibitors according to this invention.
  • the stabilized composition can comprise, as nonlimiting examples, leupeptin and PPACK in combination; leupeptin and antipain in combination; antipain and PPACK in combination; antipain, leupeptin and PPACK in combination; leupeptin and PPRACK in combination; antipain and PPRACK in combination; antipain, leupeptin and PPRACK in combination; DFP and PPACK in combination; DFP and PPRACK in combination; DFP and antipain in combination; DFP and leupeptin in combination; DFP, antipain, leupeptin and PPACK in combination; DFP, antipain, leupeptin and PPRACK in combination; DFP, antipain, leupeptin, PPACK and PPRACK in combination; etc., so as to provide a cocktail of these stabilizing ingredients.
  • the stabilizing ingredients can be formulated or combined alone or together, lyophilized if desired, or dissolved in aqueous solution or buffer prior to use, and introduced as an additive to freshly prepared laboratory samples.
  • the stabilizing ingredients comprising one or more of antipain, leupeptin, PPACK, PPRACK, or DFP, can be provided directly as an aqueous solution, a BNP stabilizing effective amount of which can be added to the plasma, or blood sample, as needed or desired, before the initial measurement of BNP.
  • the inhibitor(s) according to the present invention are added within approximately 5 to 30 minutes or less after separation of plasma from whole blood via centrifugation collection; samples are preferably frozen for storage. If serum were to be used as the sample type, inhibitors are added to the collection tube prior to whole blood collection as the process of clotting destroys BNP.
  • the stabilizing components can be provided in concentrated form, such that a mere dropperful of a concentrated preparation of the protease inhibitors, for example, can be added to a blood or plasma sample without causing any significant dilution of the blood or plasma.
  • the stabilizing components can be provided in a dropper vial or container, e.g., a container suitable for receiving a dropper or similar device, or even a syringe, for ease in dispensing the components into a sample.
  • the components are in combination, for example, a combination of leupeptin and PPACK, or a combination of antipain and PPACK, and the like, in the concentrated formulation to be added to a sample.
  • a dropper vial or container housing a protease inhibitor composition of the invention can be included in a kit for performing an assay for BNP detection in blood or plasma samples.
  • a kit for performing an assay for BNP detection in blood or plasma samples can be included in a kit for performing an assay for BNP detection in blood or plasma samples.
  • concentrated inhibitor(s) can provided at a concentration of approximately 5-10 mg/ml in frozen form, as a nonlimiting example; or as a dry powder, at approximately 5-10 mg/vial as a nonlimiting example, so as to allow straightforward dilution to about 5-10 mg/ml.
  • a 5-10 mg/ml solution(s) typically represents a 100 ⁇ -200 ⁇ stock material for the further addition to BNP-containing samples, e.g., at a ratio of 1 volume to 99-199 volumes.
  • control materials such as medical decision pools
  • materials that are made in the same blood-based matrix, e.g., plasma, as the sample undergoing analysis, e.g., a human plasma sample.
  • Such control materials must be accurate and contain stable components, as they serve as standards against which clinical decisions relating to patient treatment and outcome are made.
  • the controls have set values or levels of included materials, such as BNP; the set values or levels correspond to a cut point, i.e., a value that is used to make a medical determination or decision involving a patient, for example, the amount or level of BNP present in a patient's sample.
  • Controls having particular ranges of set levels of stabilized BNP based on particular cut points are able to be prepared for various uses, e.g., screening of a patient's sample for risk of heart attack, infarction, further cardiac disease and the like; monitoring a cardiac patient's therapy; and/or staging a cardiac patient as to degree or severity of cardiac disease.
  • the stabilizing components e.g., leupeptin, antipain, PPACK, PPRACK, DFP and combinations thereof, are advantageous in producing such control materials involving BNP in a blood matrix to prevent or significantly reduce the degradation of the BNP over time, and/or after freezing and thawing.
  • Use of one or more of the BNP-stabilizing inhibitors according to the present invention to prepare control materials allows large numbers of control samples to be made (e.g., on the order of thousands) using large quantities of material (e.g., plasma).
  • these control materials can be stored and remain stable over time, since the levels of components such as BNP in these control materials remain stable over time.
  • the values of the BNP do not vary significantly from the initial set value or cut point of the control so that read-back values remain virtually constant and reliably stationary in the stored control materials.
  • the inhibitors alone or in combination, can be added to the blood-based (e.g., plasma) matrices prior to, or at the time of, the addition of exogenous BNP (e.g., synthetic BNP), to prepare the control materials for use in BNP analysis and quantification of patient blood samples.
  • this invention provides a composition of stabilizing components, namely, one or more of the inhibitors leupeptin, antipain, PPACK, PPRACK, DFP, or combinations thereof, present in a blood collecting tube or vacutainer tube for use at the time of collecting whole blood.
  • stabilizing components namely, one or more of the inhibitors leupeptin, antipain, PPACK, PPRACK, DFP, or combinations thereof, present in a blood collecting tube or vacutainer tube for use at the time of collecting whole blood.
  • the stabilizing composition of the invention can comprise the protease inhibitors as described, e.g., leupeptin, antipain, PPACK, PPRACK, and/or DFP alone or in combination in the collection tube, either in a small amount of concentrated aqueous solution, or in a lyophilized form which solubilizes upon addition of the blood sample, or which is solubilized with a small amount of aqueous solution just prior to the collection of the blood sample.
  • a volume of the concentrated inhibitor(s) solution that does not exceed 1% of the sample volume. For example, not more than about 60 ⁇ l of concentrated inhibitor(s), or inhibitor mixture, should be added to a typical 6 ml collection tube.
  • a combination of leupeptin and PPACK is added to blood based matrices, e.g., human plasma, prior to the addition of exogenous synthetic BNP to prepare control materials, medical decision pools, and the like.
  • Controls and medical decision pools can also be prepared using a combination of stabilizing components and endogenous BNP.
  • the present invention encompasses a procedure for stabilizing BNP-containing blood samples by directly adding the inhibitor components, and combinations thereof, to collected blood samples, preferably plasma samples, prior to, at the time of, or shortly after collection and before testing in a laboratory or clinical setting.
  • These components serve as BNP inhibitor additives to fresh samples, as well as to thawed samples, particularly, freshly thawed samples, of blood, plasma, or serum.
  • Preferred is the use of a combination of leupeptin and PPACK, or leupeptin and PPRACK, in an aqueous composition to stabilize BNP in fresh or thawed plasma.
  • the addition of inhibitor(s) to a sample is preferably done as soon as possible (e.g., within minutes; preferably within about 5 minutes or less) after collection.
  • the use of the inhibitors according to the present invention affords good (e.g., ⁇ 90%) recovery of exogenous BNP in human plasma stored at room temperature ( ⁇ 20° C.) for approximately 44 hours.
  • the following Table 2 shows a dose recovery of synthetic BNP (2000 pg/ml) spiked into human plasma samples (Intergen), with and without leupeptin (50 ⁇ g/ml and PPACK (35 ⁇ g/ml) as added inhibitors.
  • sample (and BNP) storage is preferably for a time that minimizes exposure of BNP to temperatures greater than 0° C., even in the presence of inhibitor(s).
  • the present invention provides stable plasma controls for BNP determination.
  • controls can be made by spiking a fixed amount of exogenously added BNP, e.g., a recombinantly produced or synthetic form of BNP, such as BNP-32, (D. R. Murdoch et al., 1999, “Disparity between studies of the stability of BNP in blood: comparison of endogenous and exogenous peptide”, Heart , 81:212), into a human blood-based matrix, e.g., a plasma matrix, wherein the matrix contains one or more of the added inhibitor components according to the present invention, i.e., leupeptin, antipain and PPACK, or combinations thereof.
  • This feature of the invention overcomes prior difficulties in the preparation of plasma matrix controls due to the rapid degradation of spiked BNP by endogenous proteases during the preparation and value assignment procedure for such controls.
  • the stabilizing and inhibitor components e.g., leupeptin and PPACK (or PPRACK)
  • the sample has demonstrable stability, e.g., at 4° C. for at least 17 hours, without loss of activity.
  • Table 3 below presents the stability results of synthetic BNP-32 added to normal human plasma containing both leupeptin (50 ⁇ g/ml) and PPACK (35 ⁇ g/ml) in accordance with this invention: TABLE 3 After storage Before storage (17 hours at 4° C.) Sample BNP, pg/ml BNP, pg/ml % change control plasma A 45.03 45.1 0.2 control plasma B 419.69 416.2 ⁇ 0.8
  • Table 4 shows that at room temperature (RT), (22° C.), the stability of BNP-32 in the plasma sample containing the inhibitor combination as described above with respect to Table 3 was only slightly inferior to its stability at 4° C.
  • RT room temperature
  • BNP pg/ml 4°C.
  • time 0 BNP
  • time 0 control plasma
  • control plasma A 45.1 45.9 101.7 43.9 97.3 control plasma B 391.7 453.2 115.7 424.4 108.3
  • BNP-specific antibodies (Shionogi & Co., LTD, Osaka, Japan; EP542255A1/B1; JP 3297392) were used.
  • the first antibody was labeled with acridinium ester (AE) and the second antibody was labeled with biotin.
  • AE acridinium ester
  • biotin biotin
  • BNP-AE complexes retained on the PMP were treated with alkaline solution to produce a chemiluminescent signal, which was proportional to the amount of BNP captured; the signal was measured in relative light units or “RLU”.
  • the assay was carried out on an automated chemiluminescent system ADIVA:CentaurTM (Bayer Corporation, Tarrytown, N.Y.) using BNP detection reagents, such as have been described. (e.g., B. Bluestein et al., 2002, “Development of an automated test for BNP as an aid in the diagnosis and evaluation of CHF on the Bayer ADVIA Centaur ACS”, Clinical Chemistry , 48(S6):A85, Abstract C37). The results of the experiments are presented in Table 5.
  • control standards (S1-S7) were frozen in phosphate buffer until use. These standards were prepared gravimetrically by spiking synthetic BNP into physiological buffer solution.
  • Column 1 of Table 5 indicates the samples tested: Standards, S1-S7; Intergen's Human Plasma Pool (IHPP), commercially available from Intergen (Milford, Mass.), comprising normal EDTA plasma collected from healthy human donors and tested negative for hepatitis B virus, hepatitis C virus and HIV by FDA approved methods; AEBSF (i.e., [4-(2-aminoethyl)benzenesulfonylfluoride]) inhibitor; antipain inhibitor; benzamidine inhibitor; PPACK inhibitor; and KCBB (Kansas City Blood Bank) Plasma Pool, which comprised pooled normal EDTA plasma from healthy human donors and tested negative for hepatitis B virus, hepatitis C virus and HIV by FDA approved methods.
  • IHPP Intergen's Human Plasma Pool
  • AEBSF i.e
  • Column 2 of Table 5 indicates the BNP concentration, [BNP], if present.
  • Columns 3-8 of Table 5 show a stability profile of BNP in plasma samples and indicate times of assaying a sample for BNP.
  • “RLU” indicates relative light units or photon counts as quantified in the assay.
  • Column 9 of Table 5 indicates the percent signal recovered.
  • Table 5 presents data comparing two plasma samples, plasma from Intergen and plasma from KCBB. Plasma samples were spiked with an extremely high dose of synthetic BNP in order to facilitate monitoring of the BNP concentration. Plasma with BNP, but without added inhibitors, served as a negative control. BNP in KCBB samples without inhibitors was practically undetectable after 72 hours of storage; however, the same plasma with inhibitors demonstrated only a gradual decrease of BNP concentration, i.e., to ⁇ 92% of its initial value after the first week of storage. The potency of individual inhibitors was tested only for IHPP.
  • PPACK appeared to be the most potent of the tested inhibitors and provided a sufficient degree of protection to exogenous BNP for at least three days, i.e., ⁇ 95.9% of BNP was recovered. Antipain also demonstrated good protective ability ( ⁇ 90% recovery after 3 day storage). In this set of experiments, the activity of antipain outlasted that of PPACK. The effect of antipain could be observed for 4 weeks, while the activity of PPACK was essentially absent. However, as will be appreciated by the skilled practitioner, it is not uncommon for inhibitors to be unstable in some blood samples; therefore, the inhibitory activity of typically good inhibitors, e.g., PPACK, can deteriorate over time in some plasma samples, but not in all samples.
  • typically good inhibitors e.g., PPACK
  • Table 6 below presents data showing that PPACK alone successfully stabilized BNP in a sample to a level that is acceptable to reduce or inhibit BNP degradation.
  • the inhibitory activity of a combination of inhibitors, with PPACK included in the mixture allows for longevity of the inhibitory activity so as to stabilize BNP.
  • This Example presents data from additional assays performed to evaluate the effect of the inhibitor components PPACK, leupeptin, and antipain, alone and in combination, on the stability of synthetic BNP-32 in plasma over time.
  • Plasma samples were spiked with synthetic BNP-32 and stored at 4° C. for varying periods of time, i.e., Day 0, 24 hours and ⁇ 90 hours, prior to testing.
  • the assay to detect and quantify the presence of BNP at a particular time point was the same as that described in Example 1.
  • Intergen human plasma (IHP) samples containing EDTA K 2 EDTA or K 3 EDTA, in an amount of about 1.8 g/l of blood, or equivalent to ⁇ 10.8 mg per 6 ml collection tube), (Intergen #01D1707, Intergen, Milford, Mass.) were used.
  • the standards were as described in Example 1.
  • the results of the experiments performed in this Example are presented in Table 7. TABLE 7 Amount Amount of Amount of of BNP BNP BNP Present Present Present Before After After BNP Storage, 24 hr/ 90 hr/ Amount Sample Day 0 4° C. 4° C.
  • Plasma samples containing endogenous BNP were purchased from ProMedDx (Norton, Mass.) and were stored frozen. On the day of assay, the samples were thawed prior to use. Thawed samples were utilized in about 1 hour following thawing. Inhibitors were added immediately after the sample was thawed. The results are presented in Table 8.
  • Table 8 Column 2 reflects amount of BNP present in a plasma sample thawed and tested on Day 0.
  • Column 3 of Table 8 presents the amount of BNP present in the Day 0 plasma sample assayed after about 4 hours of storage at 4° C.
  • Column 4 of Table 8 presents the amount of BNP present in the same Day 0 plasma sample assayed after about 24 hours of storage at 4° C. The assay was performed as described in the above Examples. TABLE 8 Storage for Storage for Day 0 ⁇ 4 hr, 4° C. ⁇ 24 hr, 4° C.
  • Example 5 presents a comparative evaluation of several different inhibitors.
  • Table 11 below compares inhibitors of serine proteases associated with thrombolytic activity. The inhibitors were applied at their usual functional concentrations. All inhibitors except for PPACK were purchased from Calbiochem (San Diego, Calif.). Inhibitors such as aprotinin and benzamidine, which were previously tested for BNP stabilization by other investigators, were used for comparative purposes with the novel inhibitor compounds described herein.
  • AEBSF [4-(2-aminoethyl)benzenesulfonylfluoride)]
  • Plasma with inhibitor Aprotinin, 100 ⁇ g/ml 792.4 849.7 680.0 490.9 167.4 21.1 ( ⁇ 700 kallikrein inhibitory units/ml) Benzamidine, 15 mM 830.6 806.8 860.5 813.8 686.3 82.6 AEBSF, 0.5 mg/ml ( ⁇ 2 mM) 741.7 768.6 715.2 735.7 631.9 85.2 DFP, ⁇ 30 mM 853.3 809.6 859.8 882.3 830.8 97.4 PPRACK, 50 ⁇ g/ml 892.0 894.6 957.6 939.7 896.2 100.5 antipain
  • Plasma w/o inhibitor Plasma A 815.0 766.4 322.5 89.8 2.4 0.3 Plasma B 754.5 696.2 504.6 295.5 4.3 0.6 Plasma C 671.9 705.0 242.5 14.6 2.1 0.3 PPACK in A, 0.43 ⁇ g/ml 875.5 886.1 721.3 822.2 701.7 80.1 PPACK in A, 1.3 ⁇ g/ml 872.1 897.2 840.2 882.5 821.9 94.2 PPACK in A, 3.89 ⁇ g/ml 829.2 896.7 854.5 873.0 814.7 98.2 PPACK in A, 11.7 ⁇ g/ml 917.2 900.3 874.9 961.5 782.4 85.3 PPACK in A, 35 ⁇ g/ml 926.4 97
  • Example 7 presents the results of various experiments to determine the effect of PPACK on the stability of endogenous BNP.
  • 5 patient samples were kept under refrigeration for 0, 1, 8, 24, 48 and 144 hours.
  • a companion set of samples was spiked with PPACK to a final concentration of 35 ⁇ g/mL to assess the ability of this inhibitor to reduce degradation of BNP.
  • PPACK markedly retarded degradation, even at time 0.
  • the results were calculated as absolute recovery against the time 0 (1st run) measurement. TABLE 14 Storage Conditions 1st run 1 hour at 8 hours at 24 hours at (Time 0) 4° C. % recovery 4° C. % recovery 4° C.
  • diluent 1 was filtered horse serum
  • diluent 2 was heat-inactivated goat serum
  • diluent 3 was charcoal stripped defibrinated human plasma
  • diluent 4 was human defibrinated plasma (Irvine)
  • diluent 5 was human defibrinated plasma (Seracon II)
  • diluent 6 was true human serum
  • diluent 7 was delipidated, stripped plasma (Seracon II).
  • Table 17 shows that the dilution of BNP-positive plasma (i.e., plasma containing endogenous BNP) into normal plasma results in a different rate of BNP decay. This rate is specific to the plasma used as a diluent and, to a lesser degree, to the tested plasma.
  • Plasma A, B and C represent samples received from the Cardiovascular Division, Brigham and Women's Hospital, Boston, Mass. Normal plasma pool 1 was prepared in the laboratories of Bayer Corporation, Tarrytown, N.Y. from in-house donors' plasma; plasma pool 2 is the same KCBB pool as described hereinabove; and plasma pools 3 and 4 were obtained from Intergen. “Dil” refers to “diluted”.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Automatic Analysis And Handling Materials Therefor (AREA)
  • Peptides Or Proteins (AREA)
US10/465,691 2002-06-19 2003-06-19 Stabilization of brain natriuretic peptide (BNP) in blood samples, methods and compositions related thereto Abandoned US20040067889A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/465,691 US20040067889A1 (en) 2002-06-19 2003-06-19 Stabilization of brain natriuretic peptide (BNP) in blood samples, methods and compositions related thereto

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38999102P 2002-06-19 2002-06-19
US10/465,691 US20040067889A1 (en) 2002-06-19 2003-06-19 Stabilization of brain natriuretic peptide (BNP) in blood samples, methods and compositions related thereto

Publications (1)

Publication Number Publication Date
US20040067889A1 true US20040067889A1 (en) 2004-04-08

Family

ID=29720441

Family Applications (1)

Application Number Title Priority Date Filing Date
US10/465,691 Abandoned US20040067889A1 (en) 2002-06-19 2003-06-19 Stabilization of brain natriuretic peptide (BNP) in blood samples, methods and compositions related thereto

Country Status (8)

Country Link
US (1) US20040067889A1 (fr)
EP (1) EP1378242B1 (fr)
JP (1) JP2004029021A (fr)
AT (1) ATE349219T1 (fr)
AU (1) AU2003204649A1 (fr)
CA (1) CA2430889A1 (fr)
DE (1) DE60310646T2 (fr)
ES (1) ES2279911T3 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272650A1 (en) * 2004-02-17 2005-12-08 Mohapatra Shyam S Materials and methods for treatment of inflammatory and cell proliferation disorders
US20060110359A1 (en) * 2002-09-06 2006-05-25 Juan Sanchez-Ramos Cellular delivery of natriuretic peptides
US20060183681A1 (en) * 2005-02-14 2006-08-17 Bio-Rad Laboratories, Inc. Stabilized compositions containing natriuretic peptides
US20070265204A1 (en) * 2004-02-17 2007-11-15 University Of South Florida Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor
US20080070858A1 (en) * 2002-09-06 2008-03-20 Mohapatra Shyam S Materials and Methods for Treatment of Allergic Diseases
US20080108147A1 (en) * 2006-11-03 2008-05-08 Tie Wei Reduction of non-specific binding in immunoassays
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
US20080241001A1 (en) * 2002-05-13 2008-10-02 Becton, Dickinson And Company Protease Inhibitor Sample Collection System
US20090215182A1 (en) * 2008-02-27 2009-08-27 Ute Schellenberger Method, composition and device for sampling natriuretic peptides in a biological fluid
US20110236879A1 (en) * 2006-02-21 2011-09-29 Nexus, DX, Inc. Methods and compositions for analyte detection
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
CN113671197A (zh) * 2021-08-19 2021-11-19 四川沃文特生物技术有限公司 一种缓冲液、校准品、试剂盒、制备方法及用途
CN116718762A (zh) * 2023-06-09 2023-09-08 上海品峰医疗科技有限公司 一种多肽类样本稳定剂

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7445933B2 (en) 2003-07-16 2008-11-04 Abbott Laboratories, Inc. Stable calibrators or controls for measuring human natriuretic peptides
US7291501B2 (en) 2003-07-16 2007-11-06 Abbott Laboratories Stable compositions for measuring human natriuretic peptides
ATE519109T1 (de) * 2004-12-21 2011-08-15 Univ Yale Präeklampsie-diagnose
WO2007003594A1 (fr) * 2005-07-01 2007-01-11 Solvay Pharmaceuticals Gmbh Utilisation de meprine de metalloprotease et d'inhibiteurs de celle-ci
JP5065828B2 (ja) * 2006-09-26 2012-11-07 三菱化学メディエンス株式会社 ディプロチンａを含有する採血管及びそれを用いる測定法
FI20075251A0 (fi) 2007-04-13 2007-04-13 Hytest Oy Immunomääritys epästabiilien antigeenien määrittämiseksi
CN102798691A (zh) * 2011-05-21 2012-11-28 中国科学院大连化学物理研究所 一种检测血中苯丙氨酸二肽的新方法
JP7407659B2 (ja) 2019-05-30 2024-01-04 塩野義製薬株式会社 プロテアーゼ阻害剤を含有するｂｎｐ測定用標準品

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096811A (en) * 1986-03-12 1992-03-17 Genentech, Inc. Novel assay system for measuring human plasminogen actuator activity
US5541116A (en) * 1991-09-30 1996-07-30 B.R.A.H.M.S. Diagnostica Gmbh Method for the stabilization of endogenous, physiologically active peptides
US6835814B1 (en) * 1999-03-30 2004-12-28 Eli Lilly And Company Protease resistant flint analogs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992018147A1 (fr) * 1991-04-19 1992-10-29 Affinity Biotech, Inc. Formulations de microemulsions a inversion de phase
JP3555961B2 (ja) * 1991-12-25 2004-08-18 第一サントリーファーマ株式会社 安定なペプチド医薬組成物
WO1999022235A1 (fr) * 1997-10-24 1999-05-06 Shionogi & Co., Ltd. Procede d'inhibition de la decomposition de peptides natriuretiques et procede ameliore de dosage de peptides natriuretiques a l'aide desdits peptides
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096811A (en) * 1986-03-12 1992-03-17 Genentech, Inc. Novel assay system for measuring human plasminogen actuator activity
US5541116A (en) * 1991-09-30 1996-07-30 B.R.A.H.M.S. Diagnostica Gmbh Method for the stabilization of endogenous, physiologically active peptides
US6835814B1 (en) * 1999-03-30 2004-12-28 Eli Lilly And Company Protease resistant flint analogs

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645425B2 (en) 2002-05-13 2010-01-12 Becton, Dickinson And Company Protease inhibitor sample collection system
US20080241001A1 (en) * 2002-05-13 2008-10-02 Becton, Dickinson And Company Protease Inhibitor Sample Collection System
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
US20060110359A1 (en) * 2002-09-06 2006-05-25 Juan Sanchez-Ramos Cellular delivery of natriuretic peptides
US7655772B2 (en) 2002-09-06 2010-02-02 University Of South Florida Materials and methods for treatment of allergic diseases
US8623835B2 (en) 2002-09-06 2014-01-07 University Of South Florida Materials and methods for treatment of respiratory allergic diseases
US20080070858A1 (en) * 2002-09-06 2008-03-20 Mohapatra Shyam S Materials and Methods for Treatment of Allergic Diseases
US20070265204A1 (en) * 2004-02-17 2007-11-15 University Of South Florida Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor
US20050272650A1 (en) * 2004-02-17 2005-12-08 Mohapatra Shyam S Materials and methods for treatment of inflammatory and cell proliferation disorders
US20090176706A1 (en) * 2004-02-17 2009-07-09 Mohapatra Shyam S Materials and methods for treatment of inflammatory and cell proliferation disorders
US8071560B2 (en) 2004-02-17 2011-12-06 University Of South Florida Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor
US8148114B2 (en) 2004-02-17 2012-04-03 University Of South Florida Materials and methods for treatment of inflammatory and cell proliferation disorders
WO2006088624A3 (fr) * 2005-02-14 2009-04-16 Bio Rad Laboratories Compositions stabilisees contenant des peptides natriuretiques
WO2006088624A2 (fr) * 2005-02-14 2006-08-24 Bio-Rad Laboratories, Inc. Compositions stabilisees contenant des peptides natriuretiques
US20060183681A1 (en) * 2005-02-14 2006-08-17 Bio-Rad Laboratories, Inc. Stabilized compositions containing natriuretic peptides
US20110236879A1 (en) * 2006-02-21 2011-09-29 Nexus, DX, Inc. Methods and compositions for analyte detection
US20080108147A1 (en) * 2006-11-03 2008-05-08 Tie Wei Reduction of non-specific binding in immunoassays
EP2098866A1 (fr) 2008-02-27 2009-09-09 Scios Inc. Procédé, composition et dispositif pour échantillonner des peptides natriurétiques dans un liquide biologique
US20090215182A1 (en) * 2008-02-27 2009-08-27 Ute Schellenberger Method, composition and device for sampling natriuretic peptides in a biological fluid
US9482677B2 (en) 2008-02-27 2016-11-01 Scios Inc. Method, composition and device for sampling natriuretic peptides in a biological fluid
US20170003305A1 (en) * 2008-02-27 2017-01-05 Crimson U.S. Assets Llc Method, composition and device for sampling natriuretic peptides in a biological fluid
US10641781B2 (en) * 2008-02-27 2020-05-05 Crimson U.S. Assets Llc Method, composition and device for sampling natriuretic peptides in a biological fluid
US11105819B2 (en) * 2008-02-27 2021-08-31 Crimson U.S. Assets Llc Method, composition and device for sampling natriuretic peptides in a biological fluid
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
CN113671197A (zh) * 2021-08-19 2021-11-19 四川沃文特生物技术有限公司 一种缓冲液、校准品、试剂盒、制备方法及用途
CN116718762A (zh) * 2023-06-09 2023-09-08 上海品峰医疗科技有限公司 一种多肽类样本稳定剂

Also Published As

Publication number Publication date
ES2279911T3 (es) 2007-09-01
EP1378242B1 (fr) 2006-12-27
DE60310646T2 (de) 2007-10-04
JP2004029021A (ja) 2004-01-29
CA2430889A1 (fr) 2003-12-19
DE60310646D1 (de) 2007-02-08
EP1378242A1 (fr) 2004-01-07
ATE349219T1 (de) 2007-01-15
AU2003204649A1 (en) 2004-01-15

Similar Documents

Publication Publication Date Title
EP1378242B1 (fr) Méthodes et compositions destinées à la stabilisation du Brain Natriuretic Peptide (BNP) dans des prises de sang
Banfi et al. Preanalytical phase of sport biochemistry and haematology
Helfrich et al. Normotensive renal failure in systemic sclerosis
CA2073741C (fr) Extrait de thromboplastine, reactif et preparation a base de ce produit
US7674623B2 (en) Method of stabilizing human natriuretic peptides
Belenky et al. The effect of class-specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma
Skov Glomerular filtration rate in patients with severe and very severe renal insufficiency: Determined by simultaneous inulin, creatinine and 125iothalamate clearance
US7351586B2 (en) Method of making stable calibrators or controls for measuring human natriuretic peptides
JP4790818B2 (ja) 上昇した量のｄ−ダイマーを含む保存安定性細胞性全血組成物
Lott et al. Differential diagnosis of patients with abnormal serum creatine kinase isoenzymes
JP5201822B2 (ja) ガストリン放出ペプチド前駆体の免疫学的測定方法
Icard et al. Utility of C-reactive protein measurements for empyema diagnosis after pneumonectomy
Fábrega et al. Adrenomedullin in liver transplantation and its relationship with vascular complications
EP1568782A1 (fr) Diagnostic et thérapie des maladies associées à l'ADAMTS-13
Kara Relationship between red cell distribution width and serum C reactive protein levels in maintenance hemodialysis patients
Brewer et al. A technique for the processing of blood samples for subsequent assay of ATP, and an investigation of the method of standardization of the firefly-luciferase ATP assay
Al-Mondhiry et al. Hemostatic abnormalities associated with prolonged ventricular assist pumping: Analysis of 24 patients
Fricke et al. Thrombin clotting time and fibrinogen concentration in patients treated with coumadin
Johnstone Bleeding disorders in dogs: 2. Acquired disorders
Al-Yasiri et al. Correlation Between Serum Ferritin And Liver Function in Thalassemia Patients.
Schrader et al. Digoxin‐Like Immunoreactive Substance in Renal Transplant Patients
McDonald et al. Relative Serum Antiplasmin Levels in Normal and Hemophilic Dogs Treated with Choline
Thomas Renin activity in human hypertension
Wolosowicz et al. A simple method of determining e-aminocaproic acid (EACA) in urine
CN117871861A (zh) 一种蛋白s试剂和蛋白s活性检测试剂盒

Legal Events

Date Code Title Description
AS Assignment

Owner name: BAYER CORPORATION, NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BELENKY, ALEXANDER;BLUESTEIN, BARRY;REEL/FRAME:014684/0086

Effective date: 20030821

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION